GERMANTOWN, Md., May 6, 2019 /PRNewswire/ -- Neuralstem, Inc.
(Nasdaq: CUR), a biopharmaceutical company focused on the
development of nervous system therapies based on its neural stem
cell and small molecule technologies, announced that David J. Mazzo, Ph.D. has been appointed to the
Company's Board of Directors to be effective June 12, 2019. Dr. Mazzo will replace
Stanley Westreich, who is retiring
on the effective date.
"Dr. Mazzo is a seasoned executive in the biopharma space and
brings Neuralstem significant value gained over his 30 years in the
pharmaceutical and biotech industries," said Dr. Ken Carter, Executive Chairman of the Board. "He
will be an invaluable addition to our team as Neuralstem continues
down the path of developing innovative therapies to help improve
patient outcomes."
"I look forward to working with the Neuralstem team to continue
down the path of creating new therapies for patients with unmet
medical needs, as well as delivering value to our shareholders,"
said Dr. Dave Mazzo.
Dr. Mazzo brings over 30 years of experience in the
pharmaceutical industry, and currently serves as Chief Executive
Officer of Caladrius Biosciences, a clinical-stage
biopharmaceutical company committed to the development of
innovative products in cardiovascular and autoimmune diseases. Dr.
Mazzo has also served as: Chief Executive Officer and as a member
of the board of directors of Regado Biosciences, Inc., a
NASDAQ-listed biopharmaceutical company; President, Chief
Executive Officer and a director of Æterna Zentaris, Inc. and
President, Chief Executive Officer and a director of Chugai Pharma
USA, LLC, a biopharmaceutical
company which was the U.S. subsidiary of Chugai Pharmaceutical Co.,
Ltd. of Japan. In addition, Dr.
Mazzo has also held senior management and executive positions in a
number of public and private pharmaceutical and biotech
companies.
Dr. Mazzo earned a BA in the Honors Program (interdisciplinary
humanities) and a BS in chemistry from Villanova University. In addition, Dr. Mazzo
received his MS in chemistry and his PhD degree in analytical
chemistry from the University of
Massachusetts, Amherst. He was also a research fellow at the
Ecole Polytechnique Federale de Lausanne, Switzerland.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. Neuralstem's diversified portfolio of product
candidates includes its proprietary neural stem cell
technology.
The Company has two lead development candidates:
NSI-566 is a neural stem cell therapy in clinical development
for treatment of paralysis in stroke, for Amyotrophic Lateral
Sclerosis (ALS) and for chronic spinal cord injury (cSCI).
NSI-189 is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke.
Cautionary Statement Regarding Forward Looking Information
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including its
Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Investor Contact:
Sunflower Life Sciences
josh@sunflowerlifesciences.com
View original
content:http://www.prnewswire.com/news-releases/neuralstem-appoints-david-j-mazzo-phd-to-board-of-directors-300843980.html
SOURCE Neuralstem, Inc.